PPCB Propanc Biopharma, Inc.
Healthcare$1.74-1.14%ClosedMarket Cap: $1.5M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
0.16
P/S
0.00
EV/EBITDA
-0.15
DCF Value
$-16.84
FCF Yield
-267.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-151.3%
ROA
-128.1%
ROIC
-161.1%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q3 null | $0.00 | -Infinity% | $-6.4M | $-6.4M | $— | — |
| Q2 null | $0.00 | NaN% | $-3.7M | $-3.1M | $— | — |
| Q1 null | $0.00 | NaN% | $-4.7M | $-4.8M | $— | — |
| Q4 null | $0.00 | NaN% | $-3.6M | $-4.1M | $— | — |
| FY null | $0.00 | NaN% | $-57.3M | $-58.9M | $— | — |
| Q3 null | $0.00 | NaN% | $-53.1M | $-54.1M | $— | — |
| Q2 null | $0.00 | NaN% | $-213.4K | $-430.2K | $— | — |
| Q1 null | $0.00 | NaN% | $-290.8K | $-354.3K | $— | — |
| Q4 null | $0.00 | -Infinity% | $-259.9K | $-358.6K | $— | — |
| FY null | $0.00 | -Infinity% | $-1.5M | $-1.8M | $— | — |
| Q3 null | $0.00 | NaN% | $-420.9K | $-526.7K | $— | — |
| Q2 2024 | $0.00 | NaN% | $-438.0K | $-584.0K | $-1,028.19 | — |